Dr Christopher Thomas
Prosiectau fel Cyd-Ymchwiliwr
1 o 2
- 3D printing a skin model to investigate immunological control of skin cancer development (01.04.2017 - 31.03.2020)
- Biocompatible 3D printed vasculature for bioprinted tissues (01.02.2024 - 31.05.2025)
- BudSurf Trial - Stability assessment of a Budesonide + Poractant Alfa combination formulation to be used in clinical trial in extreme preterm infants (01.09.2017 - 30.06.2018)
- Characterising the role of oxidized lipids in the mechanism of epidermal barrier information (01.07.2013 - 30.09.2014)
- Core Equipment Grant (02.01.2023 - 01.07.2024)
Thomson Reuters Deutschland GmbH
Zur Giesserei 2
D-76227 Karlsruhe | Germany